The purpose of this study is to evaluate how well Lu AG09222 can prevent blood vessel dilation in a headache model.
This study will investigate the effect of preventive treatment with Lu AG09222 on vasodilation, heart rate increase, and headache induced by PACAP and VIP. Subjects will be randomised to three arms, placebo + saline, placebo + VIP and PACAP, and Lu AG09222 + VIP and PACAP. Subjects who complete the study will attend a safety follow-up visit at 10 to 12 weeks after administration of investigational medicinal product.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
25
Single dose
Single dose
Danish Headache Center Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Area under the curve (AUC) of change from start of infusion in superficial temporal artery (STA) diameter from 0 to 120 min after start of infusion of PACAP38
Time frame: 0 to 120 min after infusion
Change from start of infusion in STA diameter to 60 min after start of infusion of PACAP38
Time frame: 0 to 60 min after infusion
Maximum change from start of infusion in STA diameter between 0 and 120 min after start of infusion of PACAP38
Time frame: 0 and 120 min after infusion
AUC in change from start of infusion in facial blood flow from 0 to 120 min after start of infusion of PACAP38
Time frame: 0 to 120 min after infusion
AUC in change from start of infusion in heart rate from 0 to 120 min after start of infusion of PACAP38
Time frame: 0 to 120 min after infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.